expect a several-year window between HIV seroconversion and the need for antiretroviral therapy. However, some reports have suggested that HIV-infected persons are presenting with lower CD4 cell counts in recent years and are experiencing rapid HIV progression, which requires the introduction of HAART shortly after diagnosis [3] [4] [5] . Some of these data may be confounded, because patients may have been infected with HIV for several years before actually receiving the diagnosis.
Studies examining trends in post-seroconversion CD4 cell counts among documented HIV seroconverters during the HIV epidemic are conflicting. A recent study that examined a cohort of HIV seroconverters from Europe, Australia, and Canada suggested that initial CD4 cell counts have decreased from 1985 to 2002 [4, 6] . However, several previous studies found no significant trends in post-seroconversion CD4 cell counts over various time periods during the HIV epidemic [7] [8] [9] [10] [11] [12] , or a decreasing trend has been observed only among certain HIV transmission groups [13] . Some studies have had methodological difficulties or short periods of evaluation [11, [14] [15] [16] [17] .
Whether HIV-infected patients have presented with progressively lower CD4 cell counts over the course of the HIV epidemic remains unclear, and no recent study examining the subject has been conducted in the United States. If initial CD4 cell counts are decreasing, this could suggest that HIV has become more virulent, providing valuable information to clinicians as well as important insights regarding HIV pathogenesis on a population level. We evaluated racially diverse documented HIV seroconverters from various geographic areas in the United States to evaluate whether CD4 cell counts at diagnosis have changed during the course of the HIV epidemic.
METHODS

Study cohort.
We evaluated documented HIV seroconverters from 1985 through 2007 as part of a large cohort study to determine if post-seroconversion CD4 cell counts have changed over time. The TriService AIDS Clinical Consortium HIV Natural History Study is an ongoing, prospective observational cohort of HIV-infected persons who are Department of Defense beneficiaries (active duty members, retirees, and dependents) at 7 US military medical centers. All active duty US military personnel are confirmed to be HIV-negative prior to enlistment and undergo routine HIV screening every 1-5 years. Since the study initiation in 1985, the Natural History Study has enrolled over 4900 participants. HIV-infected participants in the study mainly acquired HIV via sexual transmission; !1% of our cohort is estimated to have used illegal drugs [18] , because of military drug policies and testing procedures.
All participants in this study were documented HIV seroconverters, with a р4-year interval (mean interval [‫ע‬SD] , years) between the last negative and first positive HIV 1.5 ‫ע‬ 0.9 test result. HIV infection status was assessed using ELISA, and positive results were confirmed by Western Blot. All included participants were antiretroviral naive and had a CD4 cell count measured within 6 months after receiving a diagnosis of HIV infection. This substudy involving 2174 participants was approved by the governing central institutional review board.
Data collection. Following enrollment, data collected from participants included demographic information (age, sex, and self-reported race/ethnicity); body mass index (calculated as weight in kilograms divided by the square of height in meters); medical histories, including medication use; and clinical laboratory studies, including WBC counts, total lymphocyte counts, CD8 cell counts, CD4 cell counts, and CD4 cell percentages (determined by flow cytometry); and HIV load (Amplicor; Roche). Viral load testing became available for our study cohort in ∼1996; viral loads measured within 6 months after HIV diagnosis were used when available. All laboratory tests were performed at the participating military medical centers, which are accredited by the Clinical Laboratory Improvement Amendments.
Statistical methods. Statistical analyses included summaries of baseline characteristics and immune-related cell counts for the study population. Data were recorded as mean values (‫ע‬SD) for continuous variables and as percentages for categorical variables. The study period of 1985-2007 was a priori divided into 4 periods according to time of HIV diagnosis: 2 periods in the pre-HAART era (1985-1990 and 1991-1995) and 2 periods in the HAART era (1996-2001 and 2002-2007) . The x 2 test was used to compare characteristics among patients from the 4 calendar periods.
Linear regression models were used to assess trends in initial CD4 cell counts across calendar periods. Models were adjusted for length of seroconversion window (i.e., time from last negative HIV test result to first positive HIV test result), time from positive HIV test result to initial CD4 cell count measurement, age, sex, race, body mass index, enrollment site, and HIV load, which was categorized into standard groupings when available (1267 participants) and categorized as "missing" when not available (907 participants); this will be referred to as the fully adjusted model. These same fully adjusted regression models were repeated for CD4 cell percentage and CD8 cell, total lymphocyte, and WBC counts. Predicted means of CD4 cell counts were computed by time period with use of marginal weighting to reflect the actual distribution of adjusting characteristics in this cohort; tests of pairwise differences used the Tukey-Kramer adjustment for multiple comparisons. In addition to adjusting for race in our fully adjusted models, a time period by race interaction was added to the fully adjusted model and tested, and separate models by race were performed. Similarly, we considered a time period by enrollment site interaction. All analyses were conducted using SAS, version 9 (SAS Institute).
RESULTS
Baseline characteristics.
The study population included 2174 documented HIV seroconverters. The participants had a mean (‫ע‬SD) age of years and 96% were men; 44% were 29 ‫ע‬ 7 white/non-Hispanic, 45% were African American, and 11% were other races (table 1). Thirty-five percent of participants had a seroconversion window of !1 year, 41% had a window of 1-2 years, 17% had a window of 2-3 years, and 7% had a window of 3-4 years. Ninety-three percent of the study cohort had a CD4 cell count measured within 3 months after receiving a diagnosis of HIV infection.
The baseline characteristics of HIV seroconverters during the ). Significant P p .98 predictors of a higher initial CD4 cell count in the adjusted model included a shorter seroconversion window, a lower initial HIV load, younger age, and white/non-Hispanic race (table 3) . There were no significant relationships between the initial CD4 cell count and time to first CD4 cell count, sex, or body mass index category. In addition, we examined enrollment site-specific trends, and the trends were similar to the overall cohort for all sites (results not shown). Fully adjusted multiple regression models that limited the analysis to only participants with HIV seroconversion windows of р2 years had similar results. In addition, we reanalyzed our data excluding participants with CD4 cell counts that were potentially measured during their acute seroconversion illness (i.e., a time from estimated date of seroconversion to first CD4 cell count of р90 days) and found similar results (data not shown).
Descriptive trends and regression analyses of other immune- (table 4) . Finally, the mean P p .002 initial WBC count fluctuated over the study period (table 2). In the final adjusted model, the WBC count was 258 cells/mL lower in 1991-1995 than in 1985-1990 ( ); there were P p .04 no significant differences in the WBC counts between 1985-1990 and the 2 other periods.
Models including race-specific effects by time period. Adjusted linear regression models were repeated, including a time period by race interaction for CD4 cell counts. Overall interactions between race and time period were not significant ( ). We also created separate models to examine changes P p .96 in the initial CD4 cell counts by race, because immune-related cell counts may differ among the races (typically lower in African Americans) and trends in CD4 cell counts over time may vary by race. The adjusted mean initial CD4 cell counts by race are shown in figure 1. Mean CD4 cell counts among white participants were significantly different across the periods; the largest difference was the decrease of 111 cells/mm 3 
from 1985-1990 to 2002-2007 (
). The mean initial CD4 cell P p .001 counts for African Americans in each period were also examined ( figure 1 ). There was a significant decrease of 111 cells/ ), but this and other differences were not statistically sig-.64 nificant because of the small sample size of this group.
DISCUSSION
Our study was conducted to determine whether HIV-infected persons have presented with progressively lower CD4 cell counts during the HIV epidemic. Our observations agree with those of other investigators, who have observed that patients starting HIV care more recently may be presenting with lower initial CD4 cell counts and requiring antiretroviral therapy initiation earlier in their disease course. Several reports have highlighted such occurrences [5] but were confounded by the lack of known HIV seroconversion dates. To avoid bias because of uncertain dates of HIV infection, we evaluated HIV-infected individuals who had documented windows during which seroconversion occurred. We observed that the initial CD4 cell count among documented HIV seroconverters in the United States significantly decreased during the HIV epidemic. Our findings confirm results from the CASCADE collaboration, which was conducted among HIV-infected persons in Europe, Australia, and Canada [4] . Although some prior studies did not observe decreases in initial CD4 cell counts over time, most of these studies had methodological difficulties or short study intervals [7, 8, 11, [14] [15] [16] [17] . Several studies examining the rate of HIV progression after diagnosis have also found that more-recent seroconverters have experienced a faster progression to low CD4 cell counts [4, 13] .
Possible explanations for a decrease in the CD4 cell count at diagnosis include changes in the host, virus, or environment over time. Because of the faster replication cycle of the virus relative to the host and the lack of known significant environmental changes, the most plausible explanation may be that the virus evolved. Because early HIV-specific cytotoxic T lymphocyte responses mediated by human leukocyte antigen recognition are associated with initial CD4 cell counts [19] , it is possible that the virus evolved with adaptation to the host, resulting in poorer cytotoxic T lymphocyte responses and early CD4 cell depletion [20, 21] . Other potential changes may include alterations in viral subtype, syncytium-induction, or the CXCR4 phenotype [12, 22, 23] ; however, these viral characteristics are not known to have significantly changed among seroconverters during the HIV epidemic in the United States. Studies examining viral isolates for adaptations that correlate with the progressive decrease in initial CD4 cell counts are needed; prior studies have been limited by small sample size and narrow study periods [24] .
The initial CD4 cell counts appeared to decrease early in the HIV epidemic, with more-recent periods demonstrating stabilization. Our findings suggest that if viral evolution was the cause of the CD4 cell count decreases early in the epidemic, it may have been inhibited by the introduction of HAART; perhaps HAART has caused an increase in the transmission of primary drug-resistant HIV strains with impaired virulence, or a loss of viral fitness and diversity attributable to antiretroviral use has occurred [25, 26] .
Our study noted that the mean initial CD4 cell count decreased by 102 cells/mm 3 during the HIV epidemic; early CD4 cell counts after seroconversion have been demonstrated to be important predictors of HIV disease progression, which suggests that our findings may be important for HIV-infected persons and their physicians. In our study, 25% of currently presenting HIV-infected patients have CD4 cell counts of !350 cells/mm 3 , which is the threshold for HAART initiation [2] , and 5% present with a CD4 cell count !200 cells/mm 3 , meeting the definition of AIDS. These data highlight the clinical importance of early HIV diagnosis and reconfirm the need for routine HIV testing.
Our study is the first, to our knowledge, to examine whether the decrease in initial CD4 cell count over time varies by race. Because of the racial diversity of our study population, we repeated our analyses stratified by race and noted that African Americans and white/non-Hispanic participants had similar decreases in initial CD4 cell counts. If the decrease in CD4 cell counts over time is a result of viral evolution, this suggests that the virus adapted to an immune determinant that is common among both racial groups.
CD4 cell percentages also decreased during the epidemic, confirming that HIV seroconverters are truly presenting with lower immune-related cell counts, because this measure is less dependent on the WBC count or the flow cytometry platform used. We also evaluated WBC counts over time to assure that changes in these values were not the reason for CD4 cell count decreases in our study; we found that patterns of change associated with WBC counts were different from that associated with CD4 cell counts. Lastly, we investigated the flow cytometry platforms at our clinical sites, and found no relationship between timing of changes in methodology and the observed CD4 cell count trends.
Limitations in our study include the predominantly male population that was evaluated. Although HIV-infected persons in the United States are predominantly men, which suggests that our findings may be generalizable, we could not evaluate changes in the initial CD4 cell count by sex. Second, HIV load measures were unavailable early in the epidemic; therefore, we were unable to determine whether viral loads increased during the same periods as the CD4 cell counts decreased. Third, although our findings may be attributable to a change in the characteristics of the study population over time, we carefully adjusted for all known factors that may have influenced CD4 cell counts. Regarding potential biases attributable to the exclusion of patients who initiated antiretroviral therapy before the initial CD4 cell counts, !1% of participants were excluded because of this criteria. Fourth, whereas other studies calculated the rate of CD4 cell decrease by year [4, 6] , our data showed that the pattern of CD4 cell decrease was not linear; therefore, data are presented by periods. Finally, our cohort does not collect data on transmission risk factors or viral characteristics, such as baseline genotypes, replicative capacity, or coreceptor phenotype; of note, among those individuals with subtype data in our network, 190% have remained infected with HIV subtype B, suggesting that clade type does not account for the observed CD4 cell count changes.
In summary, the initial CD4 cell counts among HIV seroconverters in the United States have significantly decreased during the epidemic. The decrease in the post-seroconversion CD4 cell counts occurred early in the epidemic, with stabilization since the advent of HAART. These data may provide an important clinical correlate to studies suggesting that HIV may have adapted to the host, resulting in a more virulent infection.
